Alzheimer's disease and Alzheimer's dementia: Distinct but overlapping entities

Neurobiology of Aging

Volumn 23, Issue 6, 2002, Pages 1077-1084

  Blass, John P ^a  

^a BURKE MEDICAL RESEARCH INSTITUTE   (United States)

Author keywords

Alzheimer dementia; Alzheimer disease; Causes

Indexed keywords

AMYLOID BETA PROTEIN;

AGING; ALZHEIMER DISEASE; BIOACCUMULATION; BRAIN METABOLISM; GENETIC PREDISPOSITION; HUMAN; HYPOTHESIS; INFLAMMATION; LANGUAGE; METABOLIC RATE; NEUROBIOLOGY; NEUROPATHOLOGY; NEUROTRANSMISSION; NONHUMAN; PRIORITY JOURNAL; REVIEW; SIGNAL TRANSDUCTION; STRESS;

EID: 0036862039     PISSN: 01974580     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0197-4580(02)00036-2     Document Type: Note

References (57)

1. Selkoe D.J. Alzheimer's disease: genes, proteins, and therapy. Physiol. Rev. 81:2001;741-766.
2. Robinson SR, Bishop GM. Aβ as a bioflocculant: Implications for the amyloid hypothesis of Alzheimer's disease. Neurobiol Aging 2002, this issue.
3. Crystal H.A., Dickson D., Davies P., Masur D., Grober E., Lipton R.B. The relative frequency of "dementia of unknown etiology" increases with age and is nearly 50% in nonogenarians. Arch. Neurol. 57:2000;713-719.
4. Crystal H., Dickson D., Fuld P., Masur D., Scott R., Mehler M.et al. Clinco-pathological studies in dementia: nondemented subjects with pathologically confirmed Alzheimer's disease. Neurology. 38:1988;1672-1687.
5. Polvikoski T., Sulkava R., Myllykangas L., Notkola I.L., Niinisto L., Verkkoniemi A.et al. Prevalence of Alzheimer's disease in a very elderly people: a prospective neuropathological study. Neurology. 56:2001;1690-1696.
6. Snowdon D.A. Aging and Alzheimer's disease: lessons from the Nun Study. Gerontologist. 37:1997;150-156.
7. Nolan K.A., Lino M.M., Seligman A.W., Blass J.P. Absence of vascular dementia in an autopsy series from a dementia clinic. J. Am. Geriatr. Soc. 46:1998;597-604.
8. Hachinski V., Munoz D. Vascular factors in cognitive impairment - Where are we now? Ann. NY Acad. Sci. 903:2000;1-5.
9. Volpe B.T., Petito C.K. Dementia with bilateral temporal lobe ischemia. Neurology. 35:1985;1793-1797.
10. Glenner G.G., Wong C.W. Alzheimer's disease: initial report of the purification and characterization of a novel cerebrovascular amyloid protein. Biochem. Biophys. Res. Commun. 120:1984;885-890.
11. Lee V.M., Goedert M., Trojanowski J.Q. Neurodegenerative tauopathies. Ann. Rev. Neurosci. 24:2001;1121-1159.
12. Chapman P.F., Falinska A.M., Knevett S.G., Ramsay M.F. Genes, models, and Alzheimer's disease. Trends Genet. 17:2001;254-261.
13. Anonymous. Consensus recommendations for the postmortem diagnosis of Alzheimer's disease. The National Institute on Aging and Reagan Institute Working Group on diagnostic criteria for the neuropathological assessment of Alzheimer's disease. Neurobiol Aging 1997;18:S1-2.
14. Rothweiler B., Temkin N.R., Dikmen S.S. Aging effect of psychosocial outcome in traumatic brain injury. Arch. Phys. Med. Rehabil. 79:1998;881-887.
15. Siman R., Reaume A.G., Savage M.J., Trusko S., Lin Y.G., Scott R.W.et al. Presenilin-1 P264L knock-in mutation: differential effects on Aβ production, amyloid deposition, and neuronal vulnerability. J. Neurosci. 20:2000;8717-8726.
16. Holcomb L.A., Gordon M.N., Jantzen P., Hsiao K., Duff K., Morgan D. Behavioral changes in transgenic mice expressing both amyloid precursor protein and presenilin-1 mutations: lack of association with amyloid deposits. Behav. Genet. 29:1999;177-185.
17. Schneider I., Reverse D., Dewachter I., Ris L., Caluwaerts N., Kuiperi C.et al. Mutant presenilins disturb neuronal calcium homeostasis in the brain of transgenic mice, decreasing the threshold for excitotoxicity and facilitating long-term potentiation. J. Biol. Chem. 13:2001;11539-11544.
18. Capsoni S., Ugolini G., Comparini A., Ruberti F., Bemardi N., Cattaneo A. Alzheimer-like neurodegeneration in aged anitnerve growth factor transgenic mice. Proc. Natl. Acad. Sci. USA. 97:2000;6826-6831.
19. Mattson M.P. Calcium and neuronal injury in Alzheimer's disease. Contributions of β-amyloid precursor protein mismetabolism, free radicals, and metabolic compromise. Ann. NY Acad. Sci. 747:1994;50-76.
20. Yatin S.M., Varadarajan S., Link C.D., Butterfield D.A. In vitro and in vivo oxidative stress associated with Alzheimer's amyloid β-peptide (1-42). Neurobiol. Aging. 20:1999;325-330.
21. Nunomura A., Perry G., Aliev G., Hirai K., Takeda A., Balraj E.K.et al. Oxidative damage is the earliest event in Alzheimer disease. J. Neuropathol. Exp. Neurol. 60:2001;759-767.
22. Blass J.P. Immunological treatment of Alzheimer's disease. New Eng. J. Med. 22:1999;1694-1695.
23. Blass J.P., Sheu R.K.F., Gibson G.E. Inherent abnormalities in energy metabolism in Alzheimer disease: interaction with cerebrovascular compromise. Ann. NY. Acad. Sci. 903:2000;204-221.
24. Mattson M.P., Barger S.W., Furukawa K., Bruce A.J., Wyss-Coray T., Mark R.J.et al. Cellular signaling roles of TGF-β, TNF-α, and β-APP in brain injury response and Alzheimer's disease. Brain Res. Brain Res. Rev. 23:1997;47-61.
25. Wirths O., Multhaup G., Czech C., Blanchard V., Moussaoui S., Tremp G.et al. Intraneuronal Aβ accumulation precedes plaque formation in β-amyloid precursor protein and presenilin-1 double-transgenic mice. Neurosci. Lett. 306:2001;116-120.
26. Hyman B.T., Smith C., Buldyrev I., Whelan C., Brown H., Tang M.X.et al. Autoantibodies to amyloid-β and Alzheimer's disease. Ann. Neurol. 49:2001;808-810.
27. Kalaria RN, Ince P, editors. Vascular factors in Alzheimer's disease, Ann NY Acad Sci 2000;903:1-556.
28. Snowdon D.A., Greiner L.H., Mortimer J.A., Riley K.P., Greiner P.A., Markesbery W.R. Brain infarction and the clinical expression of Alzheimer disease. The Nun Study. JAMA. 277:1997;813-817.
29. Brun A., Englund E. A white matter disorder in dementia of the Alzheimer type: a pathoanatomical study. Ann. Neurol. 19:1986;253-262.
30. Smith C.D., Snowdon D.A., Wang H., Markesbery W.R. White matter volumes and periventricular white matter hyperintensities in aging and dementia. Neurology. 54:2000;838-842.
31. de la Tore J.C. Impaired cerebromicrovascular perfusion. Summary of evidence in support of its causality in Alzheimer's disease. Ann. NY Acad. Sci. 924:2000;136-152.
32. Roos R.A., Haan J., Van Broekhoven C. Hereditary cerebral hemorrhage with amyloidosis - Dutch type: a congophilic angiopathy. An overview. Ann. NY. Acad. Sci. 640:1991;155-160.
33. Rogers J., Webster S., Lue L.F., Brachova L., Civin W.H., Emmerling M.et al. Inflammation and Alzheimer's disease pathogenesis. Neurobiol. Aging. 17:1996;681-686.
34. Eisen P. Anti-inflammatory therapy for Alzheimer's disease: implications of the prednisone trial. Acta Neurol. Scand. Suppl. 176:2000;85-89.
35. Hensley K., Robinson K.A., Gabbita S.P., Salsman S., Floyd R.A. Reactive oxygen species cell signaling and cell injury. Free Radic. Biol. Med. 28:2000;1456-1462.
36. Mecocci P., MacGarvey U., Beal M.F. Oxidative damage to mitochondrial DNA is increased in Alzheimer's disease. Ann. Neurol. 36:1994;747-751.
37. Sano M., Ernesto C., Thomas R.G., Klauber M.R., Schafer K., Grundman M.et al. A controlled trial of selegiline,α-tocopherol, or both as treatment for Alzheimer's disease. The Alzheimer's disease cooperative study. N. Eng. J. Med. 336:1997;1216-1222.
38. Blass J.P. Brain metabolism and brain disease: is metabolic deficiency the proximate cause of Alzheimer dementia? J. Dev. Neurosci. 66:2001;851-856.
39. Blass J.P., Gibson G.E. Cerebrometabolic aspects of delirium in relationship to dementia. Dement. Geriatr. Cogn. Disord. 10:1999;335-338.
40. Blass JP, Plum F. Metabolic encephalopathies in older adults. In: Katzman R, Terry RD, editors. The neurology of aging. Philadelphia: F.A. Davis, 1983. p. 189-220.
41. Gibson GE, Blass JP. Metabolism and neurotransmission. In: Lajtha A, editor. Handbook of Neurochemistry, vol. 3. 2nd Ed. NY: Plenum Press, 1983. p. 633-51.
42. Desgranges B., Baron J.C., de la Sayette V., Petit-Taboue M.C., Benali K., Landeau B.et al. The neural substrates of memory systems impairment in Alzheimer's disease. A PET study of resting brain glucose utilization. Brain. 121(Pt 4):1998;611-631.
43. Gibson G.E., Sheu K-F.R., Blass J.P. Abnormalities of mitochondrial enzymes in Alzheimer disease. J. Neural. Transm. 105:1998;855-870.
44. Gibson G.E., Haroutunian V., Zhang H., Park L.C., Shi Q., Lesser M.et al. Mitochondrial damage in Alzheimer's disease varies with apolipoprotein E genotype. Ann. Neurol. 48:2000;297-303.
45. Brown A.M., Sheu R.K-F., Mohs R., Haroutunian V., Blass J.P. Correlation of the clinical severity of Alzheimer's disease with an aberration in mitochondrial DNA (mtDNA). J. Mol. Neurosci. 16:2001;41-48.
46. Blass J.P. The mitochondrial spiral: an adequate cause of dementia in the Alzheimer syndrome. Ann. NY Acad. Sci. 924:2000;170-183.
47. Manning C.A., Ragozzino M.E., Gold P.E. Glucose enhancement of memory in patients with probable senile dementia of the Alzheimer type. Neurobiol. Aging. 14:1993;523-528.
48. Craft S., Dagago-Jack S.E., Wiethop B.V., Murphy C., Nevins R.T., Fleischman S.et al. Effects of hyperglycemia on memory and hormone levels in dementia of the Alzheimer type - A longitudinal study. Behav. Neurosci. 107:1993;926-940.
49. Blass JP. Metabolic Enhancement for the Treatment of Alzheimer Disease. Research and Practice in Alzheimer's Disease and Cognitive Decline 2002, in press.
50. de Leon M.J., Convit A., Wolf O.T., Tarshish C.Y., DeSanti S., Rusinek H.et al. Prediction of cognitive decline in normal elderly subjects with 2-[(18)F]fluoro-2-deoxy-D-glucose/poitron-emission tomography (FDG/PET). Proc. Natl. Acad. Sci. USA. 98:2001;10966-10971.
51. Gibson G.E., Park L.C., Zhang H., Sorbi S., Calingasan N.Y. Oxidative stress and a key metabolic enzyme in Alzheimer brains cultured cells and an animal model of chronic oxidative deficits. Ann. NY Acad. Sci. 893:1999;79-94.
52. Sheu K.-F.R., Blass J.P. The α-ketoglutarate dehydrogenase complex. Ann. NY Acad. Sci. 893:1999;61-78.
53. Sheu K-F.R., Brown A.M., Haroutunian V., Kristal B.S., Thaler H., Lesser M.et al. Modulation by DLST of the genetic risk of Alzheimer's disease in a very elderly population. Ann. Neurol. 45:1999;48-53.
54. Askenov M.Y., Askenova M.V., Camey J.M., Butterfield D.A. Oxidative modification of glutamine synthetase by amyloid β-peptide. Free Radic. Res. 27:1997;267-281.
55. Winblad B., Engedal K., Soinen H., Verhey F., Waldemar G., Wimo A.et al. A 1-year, randomized, placebo-controlled study of donepezil in patients with mild to moderate AD. Neurology. 57:2001;489-495.
56. Mohs R.C., Doody R.S., Morris J.C., Ieni J.R., Rogers S.L., Perdomo C.S.et al. A 1-year, placebo-controlled preservation of function survival study of donepezil in AD patients. Neurology. 57:2001;481-488.
57. Huang H.M., Gibson G.E. Altered β-adrenergic receptor-stimulated cAMP formation in cultured skin fibroblasts from Alzheimer donors. J. Biol. Chem. 268:1993;14616-14621.